Rigosertib promotes ferroptosis in colorectal cancer by increasing Keap1, reducing Nrf2/SLC7A11 signaling, and facilitating autophagic GPX4 degradation.
Colorectal cancer (CRC) ranks among the leading malignancies worldwide in both incidence and mortality, and its treatment continues to face major challenges such as chemoresistance and tumor metastasis. This study aims to investigate the potential therapeutic value and underlying mechanisms of the multikinase inhibitor...